Retevmo (selpercatinib) is a drug that targets RET mutations in solid tumors, used to treat cancer patients with this mutation.

What does full FDA approval mean?

Full approval means the FDA has approved the drug based on sufficient clinical evidence, as opposed to accelerated approval which relied on preliminary data.

How will this affect Eli Lilly's revenue?

The full approval is expected to boost Retevmo sales as it becomes available to more patients, but the company has not issued specific revenue guidance.

What cancers does Retevmo treat?

Retevmo treats solid tumors with RET fusion, including non-small cell lung cancer and medullary thyroid cancer, and now a broader range of tumors.

Eli Lilly (LLY) Wins Full FDA Approval for Retevmo in Broader Cancers

The FDA has granted full approval to Eli Lilly's Retevmo (selpercatinib) for a broader group of adult and pediatric patients with RET fusion solid tumors, converting the drug from accelerated to traditional approval and widening its labeled use.

Full FDA Approval for Retevmo

The U.S. Food and Drug Administration (FDA) has granted full approval to Eli Lilly's (NYSE:LLY) Retevmo (selpercatinib) for a broader group of adult and pediatric patients with RET fusion solid tumors. This decision shifts selpercatinib from accelerated to traditional approval and expands its labeled use across multiple tumor types.

Details of the Action

Drug: Retevmo (selpercatinib)
Regulator: FDA
Approval Type: Converted from accelerated to full (traditional) approval
Target Population: Adult and pediatric patients with RET fusion solid tumors
Expansion: Now includes a wider range of tumor types compared to the previous label

Company's Position

Eli Lilly welcomed the approval, stating that Retevmo demonstrates efficacy in RET-driven tumors. The company believes this decision strengthens its oncology portfolio and opens new commercial and clinical opportunities for the drug.

Context

The decision follows positive clinical trial results for the drug in multiple tumor types, prompting the FDA to convert the approval from accelerated to full. Retevmo initially received accelerated approval based on Phase 1 and Phase 2 data.

Potential Financial Impact

With full approval, Retevmo could see increased sales as it becomes available to a larger patient population. However, Eli Lilly has not issued specific revenue guidance for the drug. It remains to be seen how this approval will affect competition with other therapies in the market.